Foundayo is now available for adult patients with obesity and weight-related comorbidities to reduce excess body weight and maintain reduction.

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

Jazz Pharmaceuticals plc  today announced that the Company will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place ...